Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastati... by Ella Xiaoyan Du, Keith A. Betts, Travis Wang, Sophie A. Kitchen, Xuanhao He, Xin Yin, Sarah B. Guttenplan, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt

Get full text